These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17519307)

  • 1. Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes.
    Pörksen S; Nielsen LB; Kaas A; Kocova M; Chiarelli F; Orskov C; Holst JJ; Ploug KB; Hougaard P; Hansen L; Mortensen HB;
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2910-6. PubMed ID: 17519307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes.
    Nielsen LB; Ploug KB; Swift P; Ørskov C; Jansen-Olesen I; Chiarelli F; Holst JJ; Hougaard P; Pörksen S; Holl R; de Beaufort C; Gammeltoft S; Rorsman P; Mortensen HB; Hansen L;
    Eur J Endocrinol; 2007 Jun; 156(6):663-71. PubMed ID: 17535866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.
    Bollyky J; Greenbaum CJ
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2879-81. PubMed ID: 17682088
    [No Abstract]   [Full Text] [Related]  

  • 4. The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes.
    Fredheim S; Andersen ML; Pörksen S; Nielsen LB; Pipper C; Hansen L; Holst JJ; Thomsen J; Johannesen J; Mortensen HB; Svensson J
    Diabetologia; 2015 Apr; 58(4):828-34. PubMed ID: 25541633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
    N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement.
    Muñoz A; Hu M; Hussain K; Bryan J; Aguilar-Bryan L; Rajan AS
    Endocrinology; 2005 Dec; 146(12):5514-21. PubMed ID: 16123162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study.
    Pańkowska E; Błazik M; Groele L
    Diabetes Technol Ther; 2012 Jan; 14(1):16-22. PubMed ID: 22013887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
    Kielgast U; Asmar M; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2492-6. PubMed ID: 20207828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
    Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients.
    Mannucci E; Pala L; Monami M; Da Vico L; Bardini G; Dicembrini I; Ciani S; Lamanna C; Marchionni N; Rotella CM
    J Endocrinol Invest; 2010 Mar; 33(3):147-50. PubMed ID: 19783893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
    Kielgast U; Holst JJ; Madsbad S
    Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism.
    Light PE; Manning Fox JE; Riedel MJ; Wheeler MB
    Mol Endocrinol; 2002 Sep; 16(9):2135-44. PubMed ID: 12198249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine.
    Doliba NM; Qin W; Vatamaniuk MZ; Li C; Zelent D; Najafi H; Buettger CW; Collins HW; Carr RD; Magnuson MA; Matschinsky FM
    Am J Physiol Endocrinol Metab; 2004 May; 286(5):E834-43. PubMed ID: 14736703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
    Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
    Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of an oral mixed meal plus arginine and intravenous glucose, GLP-1 plus arginine to unmask residual islet function in longstanding type 1 diabetes.
    Uitbeijerse BS; Nijhoff MF; de Koning EJP
    Am J Physiol Endocrinol Metab; 2024 May; 326(5):E673-E680. PubMed ID: 38446636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.